Trial · NCT02563574
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | FMRI images will be performed for changes in the brain between the groups | Baseline and 6 month follow-up | Cerebral metabolite abnormalities |
| Secondary | Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-IV (SCID) | Baseline | A structured interview given to participants in order to assess current and past alcohol use and dependence |
| Secondary | Lifetime Alcohol and Drug Use History | Baseline | This interview will be conducted at baseline to gather information about age of onset of alcohol use, period of heaviest drinking, most drinks consumed on a single day, and number of drug classes used lifetime. |
| Secondary | Kreek-McHugh-Schluger-Kellogg (KMSK) Scale | Baseline, 3-month, 6-month, and 12-month follow-ups. | Developed as a research measure of drug use severity in accordance with DSM-IV criteria, the KMSK is reliable and valid, quantifying frequency, duration, and amount of individual drug use. |
| Secondary | Timeline Followback (TLFB) | Baseline, 3-month, 6-month, and 12-month follow-ups. | The TLFB interview will be used to assess recent alcohol use at baseline, as well as during the follow-up intervals. The TLFB interview is a calendar-assisted structured interview which provides a way to cue memory so that accurate recall is enhanced. The TLFB will provide data on the percentage of drinking days, drinks consumed per week, and the percentage of heavy drinking days. |
| Secondary | Urine Drug Screen | Baseline, 3-month, 6-month, and 12-month follow-ups. | Urine drug screens will be performed using Varian's TestCup Pro5, testing for benzodiazepines, amphetamines, opiates, \& cocaine. |
| Secondary | Short Inventory of Problems (SIP) | Baseline, 3-month, 6-month, and 12-month follow-ups. | The SIP assesses 15 negative consequences of alcohol use over the chosen time period (in this case 3 months) and has been found to have good psychometric properties. Maximum score is 45 |
| Secondary | Epworth Sleepiness Scale (ESS) | Baseline, 3-month, 6-month, and 12-month follow-ups. | The ESS proposes eight daytime scenarios, and the participant is asked to rate how likely they are to fall asleep in each situation on a four-point scale (0-3). |
| Secondary | Center for Epidemiological Studies-Depression Scale (CES-D) | Baseline, 3-month, 6-month, and 12-month follow-ups. | A 20-item screening test for depression and depressive disorder |
| Secondary | Beck Anxiety Inventory | Baseline, 3-month, 6-month, and 12-month follow-ups. | 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety |
| Secondary | Early Life Stress Questionnaire (ELSQ) | Baseline | A 5-section self-report questionnaire assessment of adverse childhood events |
| Secondary | The Frontal System Behavioral Scale (FrSBe) | Baseline, 3-month, 6-month, and 12-month follow-ups. | A 46-item self-report questionnaire designed to measure behavior related to frontal systems damage |
| Secondary | Medical Outcomes Study HIV Health Survey (MOS-HIV) | Baseline, 3-month, 6-month, and 12-month follow-ups. | A 35-item self-report questionnaire designed in order to assess functional status and well-being among HIV-positive individuals |
| Secondary | Montreal Cognitive Assessment (MoCA) | Baseline, 3-month, 6-month, and 12-month follow-ups. | measurement used to screen for dementia and mild cognitive impairment |
| Secondary | Hopkins Verelan Learning Test Revised (HVLT-R) | Baseline, 3-month, 6-month, and 12-month follow-ups. | cognitive assessment that measures verbal learning and memory |
| Secondary | Brief Visuospatial Memory Test Revised (BVMT-R) | Baseline, 3-month, 6-month, and 12-month follow-ups. | A measure of visuospatial memory |
| Secondary | Paced Auditory Serial Addition Test (PASAT-1) | Baseline, 3-month, 6-month, and 12-month follow-ups. | A cognitive assessment which measures visuospatial memory |
| Secondary | WAIS-3 Letter Number Sequencing | Baseline, 3-month, 6-month, and 12-month follow-ups. | 7-item cognitive assessment with a total of 21 maximum points |
| Secondary | WAIS-3 Digit Symbol | Baseline, 3-month, 6-month, and 12-month follow-ups. | A timed neuropsychological test sensitive to brain damage, dementia, age and depression consisting of digit-symbol pairs followed by a list of digits |
| Secondary | WAIS-3 Symbol Search | Baseline, 3-month, 6-month, and 12-month follow-ups. | Cognitive assessment measuring processing speed with a total max score of |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02563574/registered